Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension: The SUPER-2 Study

2012 ◽  
Vol 2012 ◽  
pp. 124-125
Author(s):  
C.D. Spradley
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Treatment ◽  
Sildenafil Citrate ◽  
Long Term Treatment ◽  
Pulmonary Arterial

Long-term Treatment With Sildenafil Citrate in Pulmonary Arterial Hypertension

CHEST Journal ◽  
2011 ◽  
Vol 140 (5) ◽  
pp. 1274-1283 ◽  
Author(s):  
Lewis J. Rubin ◽  
David B. Badesch ◽  
Thomas R. Fleming ◽  
Nazzareno Galiè ◽  
Gerald Simonneau ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Treatment ◽  
Sildenafil Citrate ◽  
Long Term Treatment ◽  
Pulmonary Arterial

LONG-TERM TREATMENT WITH SILDENAFIL CITRATE IN PULMONARY ARTERIAL HYPERTENSION

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 40S ◽  
Author(s):  
Lewis J. Rubin ◽  
David Badesch ◽  
Thomas Fleming ◽  
Nazzareno GaliΦ ◽  
Gerald Simonneau ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Treatment ◽  
Sildenafil Citrate ◽  
Long Term Treatment ◽  
Pulmonary Arterial

scholarly journals Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension

2016 ◽  
Vol 311 (4) ◽  
pp. R721-R726 ◽  
Author(s):  
Martine Clozel
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Structural Changes ◽  
Term Treatment ◽  
Vasopressin Release ◽  
Long Term Treatment ◽  
Pulmonary Arterial ◽  
Kinetics Of

Endothelin receptor antagonists (ERAs) are used for the treatment of pulmonary arterial hypertension (PAH). Macitentan, a dual (ETA+ETB) ERA approved for the long-term treatment of PAH, was discovered through a tailored research program aimed at improving efficacy and safety over the existing ERAs. The goal of improved efficacy was based on the understanding that not only the ETA receptor but also the ETB receptor contributed to the hemodynamic and structural changes induced by endothelin-1 (ET-1) in pathological conditions and on the predefined requirements for optimal tissue penetration and binding kinetics of the antagonist. The goal of improved safety was based on the discovery of the role of ETB receptors in vascular permeability and vasopressin release and on the elucidation of the mechanism by which bosentan (the first approved oral dual ETA/ETB ERA) caused liver enzyme changes. Our intention was to design a molecule that would block ETA and ETB receptors optimally and would not interfere with bile salt elimination. This review takes us through the drug discovery journey that led to the discovery, development, and registration of macitentan.

scholarly journals Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

Circulation ◽  
2003 ◽  
Vol 108 (17) ◽  
pp. 2066-2069 ◽  
Author(s):  
Evangelos D. Michelakis ◽  
Wayne Tymchak ◽  
Michelle Noga ◽  
Linda Webster ◽  
Xi-Chen Wu ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Functional Capacity ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Pulmonary Arterial

Long-term Treatment With Oral Sildenafil in Addition to Continuous IV Epoprostenol in Patients With Pulmonary Arterial Hypertension

CHEST Journal ◽  
2003 ◽  
Vol 123 (4) ◽  
pp. 1293-1295 ◽  
Author(s):  
Leopold Stiebellehner ◽  
Ventzislav Petkov ◽  
Karin Vonbank ◽  
Georg Funk ◽  
Peter Schenk ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Pulmonary Arterial

Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients

2020 ◽  
Vol 36 (6) ◽  
pp. 921-928
Author(s):  
Nobuhiro Tahara ◽  
Hiroaki Dobashi ◽  
Keiichi Fukuda ◽  
Masanori Funauchi ◽  
Masaru Hatano ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Japanese Patients ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document